KBY Biotech Indexv0.0.34
Search
← Pipeline|MIM-1147

MIM-1147

Phase 2
By Mimetogen
Source: Trial-derived·Trials: 1
Modality
Peptide
MOA
RAS(ON)i
Target
TYK2
Pathway
Sphingolipid
AngelmanNBHS
Development Pipeline
Preclinical
~Jul 2016
→ ~Oct 2017
Phase 1
~Jan 2018
→ ~Apr 2019
Phase 2
Jul 2019
→ Oct 2030
Phase 2Current
NCT07468606
1,259 pts·Angelman
2019-07→2030-10·Completed
1,259 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-10-264.6y awayPh2 Data· Angelman
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2
Complet…
Catalysts
Ph2 Data
2030-10-26 · 4.6y away
Angelman
Completed|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT07468606Phase 2AngelmanCompleted1259DAS28
Competitors (10)
DrugCompanyPhaseTargetMOA
VoxacilimabPfizerPhase 2TYK2CAR-T BCMA
MRK-3732Merck & CoPhase 1TYK2PARPi
MRK-6781Merck & CoApprovedTIGITRAS(ON)i
SNY-9073SanofiPhase 2B7-H3RAS(ON)i
TixarelsinVertex PharmaPhase 1ALKRAS(ON)i
FixatuximabLegend BiotechPreclinicalCFTRRAS(ON)i
ION-1378IonisNDA/BLATROP-2RAS(ON)i
180-3597Innovent BioPreclinicalSHP2RAS(ON)i
COR-9566CorceptApprovedTYK2HPK1i
SND-9531SyndaxPhase 3TYK2AuroraAi